207 related articles for article (PubMed ID: 16323973)
1. Naftidrofuryl: a review of its use in the treatment of intermittent claudication.
Goldsmith DR; Wellington K
Drugs Aging; 2005; 22(11):967-77. PubMed ID: 16323973
[TBL] [Abstract][Full Text] [Related]
2. A new study demonstrates the efficacy of naftidrofuryl in the treatment of intermittent claudication. Findings of the Naftidrofuryl Clinical Ischemia Study (NCIS).
Kieffer E; Bahnini A; Mouren X; Gamand S
Int Angiol; 2001 Mar; 20(1):58-65. PubMed ID: 11342997
[TBL] [Abstract][Full Text] [Related]
3. The limits of evidence in drug approval and availability: a case study of cilostazol and naftidrofuryl for the treatment of intermittent claudication.
Hong H; Mackey WC
Clin Ther; 2014 Aug; 36(8):1290-301. PubMed ID: 25012728
[TBL] [Abstract][Full Text] [Related]
4. Naftidrofuryl for intermittent claudication: meta-analysis based on individual patient data.
De Backer T; Vander Stichele R; Lehert P; Van Bortel L
BMJ; 2009 Mar; 338():b603. PubMed ID: 19276131
[TBL] [Abstract][Full Text] [Related]
5. Naftidrofuryl for intermittent claudication.
de Backer TL; Vander Stichele R; Lehert P; Van Bortel L
Cochrane Database Syst Rev; 2012 Dec; 12(12):CD001368. PubMed ID: 23235580
[TBL] [Abstract][Full Text] [Related]
6. Naftidrofuryl can enhance the quality of life in patients with intermittent claudication.
Spengel F; Brown TM; Poth J; Lehert P
Vasa; 1999 Aug; 28(3):207-12. PubMed ID: 10483329
[TBL] [Abstract][Full Text] [Related]
7. Findings of the Naftidrofuryl in Quality of Life (NIQOL) European study program.
Spengel F; Clément D; Boccalon H; Liard F; Brown T; Lehert P
Int Angiol; 2002 Mar; 21(1):20-7. PubMed ID: 11941270
[TBL] [Abstract][Full Text] [Related]
8. Naftidrofuryl in quality of life (NIQOL). A Belgian study.
D'Hooge D; Lehert P; Clement DL
Int Angiol; 2001 Dec; 20(4):288-94. PubMed ID: 11782694
[TBL] [Abstract][Full Text] [Related]
9. New treatment options in intermittent claudication: the US experience.
Hiatt WR
Int J Clin Pract Suppl; 2001 Apr; (119):20-7. PubMed ID: 11355276
[TBL] [Abstract][Full Text] [Related]
10. Cost effectiveness of cilostazol compared with naftidrofuryl and pentoxifylline in the treatment of intermittent claudication in the UK.
Guest JF; Davie AM; Clegg JP
Curr Med Res Opin; 2005 Jun; 21(6):817-26. PubMed ID: 15969881
[TBL] [Abstract][Full Text] [Related]
11. Systematic review of the efficacy of cilostazol, naftidrofuryl oxalate and pentoxifylline for the treatment of intermittent claudication.
Stevens JW; Simpson E; Harnan S; Squires H; Meng Y; Thomas S; Michaels J; Stansby G
Br J Surg; 2012 Dec; 99(12):1630-8. PubMed ID: 23034699
[TBL] [Abstract][Full Text] [Related]
12. Oral naftidrofuryl. A review of its pharmacology and therapeutic use in the management of peripheral occlusive arterial disease.
Barradell LB; Brogden RN
Drugs Aging; 1996 Apr; 8(4):299-322. PubMed ID: 8920176
[TBL] [Abstract][Full Text] [Related]
13. Naftidrofuryl for intermittent claudication.
De Backer TL; Vander Stichele R; Lehert P; Van Bortel L
Cochrane Database Syst Rev; 2008 Apr; (2):CD001368. PubMed ID: 18425872
[TBL] [Abstract][Full Text] [Related]
14. A controlled trial of naftidrofuryl (Praxilene) in the treatment of intermittent claudication.
Clyne CA; Galland RB; Fox MJ; Gustave R; Jantet GH; Jamieson CW
Br J Surg; 1980 May; 67(5):347-8. PubMed ID: 6992909
[TBL] [Abstract][Full Text] [Related]
15. [The antagonist of type-II serotonin receptors naftidrofuryl in the treatment of patients with intermittent claudication].
Komarov AL; Panchenko EP; Eshkeeva AR; Dobrovol'skiĭ AB; Titaeva EV; Karpov IuA
Ter Arkh; 1996; 68(2):49-53. PubMed ID: 8771659
[TBL] [Abstract][Full Text] [Related]
16. [Effect of naftidrofuryl on physiological walking distance in patients with intermittent claudication].
Boccalon H; Lehert P; Mosnier M
Ann Cardiol Angeiol (Paris); 2001 Apr; 50(3):175-82. PubMed ID: 12555510
[TBL] [Abstract][Full Text] [Related]
17. [Naftidrofuryl in arterial obstructive disease: A systematic revue of the literature].
Bourrion B; Hazard A; Baltazard H; Sebbag P; Fournier L; François M
Rev Med Interne; 2020 Feb; 41(2):89-97. PubMed ID: 31669163
[TBL] [Abstract][Full Text] [Related]
18. The effect of naftidrofuryl (Praxilene) on intermittent claudication.
Waters KJ; Craxford AD; Chamberlain J
Br J Surg; 1980 May; 67(5):349-51. PubMed ID: 6992910
[TBL] [Abstract][Full Text] [Related]
19. A systematic review and economic evaluation of cilostazol, naftidrofuryl oxalate, pentoxifylline and inositol nicotinate for the treatment of intermittent claudication in people with peripheral arterial disease.
Squires H; Simpson E; Meng Y; Harnan S; Stevens J; Wong R; Thomas S; Michaels J; Stansby G
Health Technol Assess; 2011 Dec; 15(40):1-210. PubMed ID: 22142554
[TBL] [Abstract][Full Text] [Related]
20. Treatment of stage II chronic arterial disease of the lower limbs with the serotonergic antagonist naftidrofuryl: results after 6 months of a controlled, multicenter study.
Adhoute G; Andreassian B; Boccalon H; Cloarec M; Di Maria G; Lefebvre O; Mondine P; Plagnol P; Pointel JP; Quancard X
J Cardiovasc Pharmacol; 1990; 16 Suppl 3():S75-80. PubMed ID: 1369725
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
